The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.

2.

Radionuclide-Containing Combo Slows Metastatic Prostate Cancer, Improves Survival

3.

CAR T cells improve patients' quality of life: a study

4.

No increased risk of childhood cancer near UK nuclear sites, study finds

5.

Newly identified T-cell subtype may explain treatment-resistant childhood leukemia


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot